Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tolerx to initiate Phase III diabetes trial
The Phase III study, known as Defend, will be conducted at multiple centers in North America and Europe and will evaluate whether a single course of otelixizumab reduces
The Phase III study, known as Defend, will be conducted at multiple centers in North America and Europe and will evaluate whether a single course of otelixizumab reduces
Under the terms of the agreement, Grunenthal will supply Obecure with betahistine and matching placebo tablets for use in its upcoming clinical studies. Pending successful development and receipt
In this study, the drug significantly reduced itch symptoms in patients with chronic idiopathic urticaria (CIU), or hives of unknown cause that last for a period of at
Under the terms of the merger agreement, EP MedSystems shareholders will receive $3 of consideration for each EP MedSystems share they own, with the option of receiving that
The net proceeds from this offering will be used for clinical development of existing product candidates and other general corporate purposes. The closing of the transaction is expected
CMC Icos will be responsible for process development, manufacturing scale-up and current good manufacturing practices (cGMP) manufacturing of GGF2. Acorda plans to use the supply of GGF2 produced
This randomized, dual-arm Phase II study will evaluate IMC-A12 as a single agent and in combination with Erbitux (cetuximab) in patients with metastatic head and neck cancer who
The trial is a multi-center, multi-national, randomized, double-blind, placebo-controlled study. The primary objective of the study is to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo
The transaction was unanimously approved by the boards of directors of both companies. Upon completion of the acquisition, Millennium will become a wholly-owned subsidiary of Takeda, and will
As of the data cutoff date, 205 of the 349 patients randomized have experienced disease progression (relapsed) according to investigator determination. Median follow-up for ongoing patients is 31